{{Rsnum
|rsid=28364072
|Gene=FCER2
|Chromosome=19
|position=7690399
|Orientation=plus
|GMAF=0.3623
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=FCER2
}}{{PharmGKB
|RSID=rs28364072
|Name_s=FCER2:T2206C
|Gene_s=FCER2
|Feature=Intron
|Evidence=PubMed ID:17980418
|Annotation=This variant is associated with severe exacerbations with asthma in both white and african american childen. This variant also leads to decreased FEER2 expression and may be used to predict treatment outcome in asthma.
|Drugs=budesonide; nedocromil
|Drug Classes=
|Diseases=Asthma
|Curation Level=Curated
|PharmGKB Accession ID=PA162356003
}}

{{PMID Auto
|PMID=19077707
|Title=Pharmacogenetics of asthma.
|OA=1
}}

{{PMID Auto
|PMID=19845913
|Title=Interaction of functional FCER2 promoter polymorphism and phenotype-associated haplotypes.
}}

{{PMID Auto
|PMID=24102092
|Title=Genetic variations of the FCER2 gene and asthma susceptibility in north Indian children: a case-control study
}}

{{PMID Auto
|PMID=25091946
|Title=Admixture of beneficial and unfavourable variants of GLCCI1 and FCER2 in Roma samples can implicate different clinical response to corticosteroids
}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}